MindMaze Therapeutics

MindMaze Therapeutics (previously Relief Therapeutics) is a Swiss med-tech company advancing and commercialising a proprietary driven platform focused on neurotherapeutic solutions to treat neurological diseases (such as stroke and TBI), integrating software-based treatments with innovative technology, data and AI to improve patient outcomes.

Equities

Equities by Sector

Sectors

Thematics

Latest

Inside the mind of the investor: Holland Advisors

Edison explains: Private credit demystified

Edison explains: Finfluencers – #Trending or toxic?

Audiovisual

Latest

In the chair with Mutares’ Johannes Laumann on US expansion, a record deal and growth momentum

Murray International Trust – equity proposition

Baillie Gifford US Growth Trust – equity proposition

About Edison

About Edison

Careers

MindMaze Therapeutics (SIX: MMTX)

Latest Insights

MindMaze Therapeutics — The next frontier of precision neurotherapeutics

Sector

Equity Analyst

Key Management

Research

Deutsches Eigenkapitalforum (EKF) 2023 healthcare

VolitionRx – Decoding the DNA of cancer

ASCO 2023 key takeaways

Machine learning in drug development

Outlook for 2023: Biotechs remain central to novel drug development

Oncology ABCs (part four): Blood cancers (AML) – notable innovations

Cell and gene therapies

Drug delivery platforms

Oncology ABCs (part three) – thinking outside the box in women’s cancer

Neuroscience comeback

IPO apocalypse

Oncology ABCs (part two) – vaccines: niche no longer

ESG, moving beyond the box tick

Oncology ABCs (part one) – a small-cap biopharma prospectus series

Cannabinoid manufacturing – Innovative approaches to the production of cannabinoids

Artificial intelligence in drug discovery

Biosynthesis – Taking the cannabinoid market to new heights

Seven things every investor should know about SIGA technologies & biological weapons

Confidence renewed as new COVID-19 vaccines demonstrate protection against emergent strains and efficacy with a single-dose regimen

Edison Exhibits- antibiotic development

The next wave in AMD

The A-B-T of biosimilars- Explaining contemporary life science issues

Cannabinoid Therapies- The coming retail wave

Cannabinoid Therapies- Therapeutics turning a corner

Trial outcomes and value – Explaining contemporary clinical trial issues

Drug pricing – Market access and reimbursement

The diagnostics sector

ASCO 2017

Deutsche Börse Eigenkapitalforum 2014 Research Guide

Edison healthcare quarterly: A boost for allergy immunotherapy

ASX Spotlight Conference – London, 6 March 2014

ASX Small to Mid Caps Conference – London, 7 March 2013

Edison healthcare quarterly: Boom times for US biotech

Edison healthcare quarterly: Crisis? What crisis?

Edison healthcare quarterly: How to please some of the people some of the time